DexCom (NASDAQ:DXCM) Price Target Lowered to $105.00 at Oppenheimer

DexCom (NASDAQ:DXCM) had its target price lowered by Oppenheimer from $115.00 to $105.00 in a report published on Friday, Benzinga reports. Oppenheimer currently has an outperform rating on the medical device company’s stock.

Several other analysts also recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, October 12th. Wells Fargo & Company boosted their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday. Robert W. Baird boosted their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Finally, Royal Bank of Canada dropped their target price on DexCom from $130.00 to $120.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Down 1.8 %

Shares of NASDAQ:DXCM opened at $72.10 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50-day moving average price of $70.11 and a 200 day moving average price of $97.65. The company has a market cap of $28.67 billion, a price-to-earnings ratio of 46.69, a PEG ratio of 2.26 and a beta of 1.18.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock valued at $126,390 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of large investors have recently made changes to their positions in the business. Stephens Investment Management Group LLC increased its position in shares of DexCom by 2.9% during the third quarter. Stephens Investment Management Group LLC now owns 684,485 shares of the medical device company’s stock worth $45,888,000 after purchasing an additional 19,279 shares in the last quarter. AustralianSuper Pty Ltd increased its position in shares of DexCom by 54.8% during the third quarter. AustralianSuper Pty Ltd now owns 15,725 shares of the medical device company’s stock worth $1,054,000 after purchasing an additional 5,568 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of DexCom by 1.6% during the third quarter. New York State Teachers Retirement System now owns 366,308 shares of the medical device company’s stock worth $24,557,000 after purchasing an additional 5,804 shares in the last quarter. Avitas Wealth Management LLC increased its position in shares of DexCom by 20.2% during the third quarter. Avitas Wealth Management LLC now owns 6,475 shares of the medical device company’s stock worth $434,000 after purchasing an additional 1,086 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of DexCom by 103.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,306 shares of the medical device company’s stock worth $356,000 after purchasing an additional 2,692 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.